Accuracy of angiogenic biomarkers at ≤20 weeks' gestation in predicting the risk of pre-eclampsia: A WHO multicentre study

Pregnancy Hypertension

Volumn 5, Issue 4, 2015, Pages 330-338

  Widmer, Mariana ^a   Cuesta, Cristina ^b   Khan, Khalid S ^c   Conde Agudelo, Agustin ^d,e   Carroli, Guillermo ^b   Fusey, Shalini ^f   Karumanchi, S Ananth ^g   Lapaire, Olav ^h   Lumbiganon, Pisake ⁱ   Sequeira, Evan ^j   Zavaleta, Nelly ^k   Frusca, Tiziana ^l,m   Gülmezoglu, A Metin ^a   Lindheimer, Marshall D ⁿ  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b Centro Rosarino de Estudios Perinatales   (Argentina)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f GOVERNMENT MEDICAL COLLEGE   (India)

^g HARVARD MEDICAL SCHOOL   (United States)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ KHON KAEN UNIVERSITY   (Thailand)

^j AGA KHAN UNIVERSITY   (Kenya)

^k INSTITUTO DE INVESTIGACIÓN NUTRICIONAL   (Peru)

^l UNIVERSITY OF BRESCIA   (Italy)

^m UNIVERSITY OF PARMA   (Italy)

ⁿ UNIVERSITY OF CHICAGO   (United States)

more..

Author keywords

Angiogenic biomarkers; Pre eclampsia; Screening

Indexed keywords

BIOLOGICAL MARKER; ENDOGLIN; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG; ANGIOGENIC PROTEIN; PGF PROTEIN, HUMAN; PLACENTA PROTEIN; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GESTATIONAL AGE; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PREECLAMPSIA; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE; ARGENTINA; BLOOD; CLINICAL TRIAL; COLOMBIA; FIRST TRIMESTER PREGNANCY; INDIA; ITALY; KENYA; PERU; PRE-ECLAMPSIA; PREGNANCY; SECOND TRIMESTER PREGNANCY; SWITZERLAND; THAILAND; URINE; WORLD HEALTH ORGANIZATION;

ADULT; ANGIOGENIC PROTEINS; ARGENTINA; BIOMARKERS; COLOMBIA; FEMALE; HUMANS; INDIA; ITALY; KENYA; PERU; PLACENTA GROWTH FACTOR; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SWITZERLAND; THAILAND; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; WORLD HEALTH ORGANIZATION;

EID: 84947866508     PISSN: 22107789     EISSN: 22107797     Source Type: Journal    
DOI: 10.1016/j.preghy.2015.09.004     Document Type: Article

References (32)

1. L. Say, D. Chou, A. Gemmill, O. Tuncalp, A.B. Moller, J. Daniels, and et al. Global causes of maternal death: a WHO systematic analysis Lancet Global Health 2 6 2014 E323 E333
2. L. Say, A. Donner, A.M. Gulmezoglu, M. Taljaard, and G. Piaggio The prevalence of stillbirths: a systematic review Reproductive Health 3 2006 1
3. S.E. Maynard, J.Y. Min, J. Merchan, K.H. Lim, J. Li, S. Mondal, and et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia J. Clin. Investig. 111 5 2003 649 658
4. C.E. Powe, R.J. Levine, and S.A. Karumanchi Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease Circulation 123 24 2011 2856 2869
5. M. Widmer, J. Villar, A. Benigni, A. Conde-Agudelo, S.A. Karumanchi, and M. Lindheimer Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review Obstet. Gynecol. 109 1 2007 168 180
6. R. Romero, J.K. Nien, J. Espinoza, D. Todem, W. Fu, H. Chung, and et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate J. Matern. Fetal Neonatal Med. 21 1 2008 9 23
7. R.J. Levine, C. Lam, C. Qian, K.F. Yu, S.E. Maynard, B.P. Sachs, and et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia New Engl. J. Med. 355 10 2006 992 1005
8. C.E. Kleinrouweler, M.M. Wiegerinck, C. Ris-Stalpers, P.M. Bossuyt, J.A. van der Post, P. von Dadelszen, and et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis BJOG 119 7 2012 778 787
9. J. Villar, H. Ba'aqeel, G. Piaggio, P. Lumbiganon, J. Miguel Belizan, U. Farnot, and et al. WHO antenatal care randomised trial for the evaluation of a new model of routine antenatal care Lancet 357 9268 2001 1551 1564
10. National Institute for Health Care Excellence. Hypertension in pregnancy, The management of hypertensive disorders during pregnancy, UK2010.
11. J. Villar, H. Abdel-Aleem, M. Merialdi, M. Mathai, M.M. Ali, N. Zavaleta, and et al. World Health Organization randomized trial of calcium supplementation among low calcium intake pregnant women Am. J. Obstet. Gynecol. 194 3 2006 639 649
12. A. Conde-Agudelo, J. Villar, and M. Lindheimer World Health Organization systematic review of screening tests for preeclampsia Obstet. Gynecol. 104 6 2004 1367 1391
13. C.A. Meads, J.S. Cnossen, S. Meher, A. Juarez-Garcia, G. ter Riet, L. Duley, and et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling Health Technol. Assess. 12 (6):iii-iv 2008 1 270
14. Geoff Der, and BSE Applied Medical Statistics Using SAS 2012 Chapman and Hall/CRC October 1
15. A. Agresti Categorical Data Analysis Second ed. 2002 John Wiley & Sons New York
16. P.D. Allison Logistic Regression Using the SAS System: Theory and Application 1999 SAS Institute Inc. Cary, NC
17. R. Jaeschke, G.H. Guyatt, D.L. Sackett, G. Guyatt, E. Bass, P. Brilledwards, and et al. Users guides to the medical literature. 3. How to use an article about a diagnostic-test. B. what are the results and will they help me in caring for my patients JAMA 271 9 1994 703 707
18. C.K. Enders, Applied missing data analysis. sciences Mits, ed. Guilford Press, New York, 2010.
19. E.R. DeLong, D.M. DeLong, and D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 3 1988 837 845
20. T.F. McElrath, K.H. Lim, E. Pare, J. Rich-Edwards, D. Pucci, R. Troisi, and et al. Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy Am. J. Obstet. Gynecol. 207 (5):407 2012 e1 e7
21. L. Myatt, R.G. Clifton, J.M. Roberts, C.Y. Spong, J.C. Hauth, M.W. Varner, and et al. First-trimester prediction of preeclampsia in nulliparous women at low risk Obstet. Gynecol. 119 6 2012 1234 1242
22. A.O. Odibo, C.C. Rada, A.G. Cahill, K.R. Goetzinger, M.G. Tuuli, L. Odibo, and et al. First-trimester serum soluble fms-like tyrosine kinase-1, free vascular endothelial growth factor, placental growth factor and uterine artery Doppler in preeclampsia J. Perinatol. 33 9 2013 670 674
23. R.W. Powers, A. Jeyabalan, R.G. Clifton, P. Van Dorsten, J.C. Hauth, M.A. Klebanoff, and et al. Soluble fms-Like Tyrosine Kinase 1 (sFlt1), Endoglin and Placental Growth Factor (PlGF) in Preeclampsia among High Risk Pregnancies PLoS ONE 5 10 2010
24. L.C. Poon, N.A. Kametas, N. Maiz, R. Akolekar, and K.H. Nicolaides First-trimester prediction of hypertensive disorders in pregnancy Hypertension 53 5 2009 812 818
25. J. Espinoza, R. Romero, J.K. Nien, R. Gomez, J.P. Kusanovic, L.F. Goncalves, and et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor Am. J. Obstet. Gynecol. 196 (4):326 2007 e1 13
26. P.F. Whiting, A.W. Rutjes, M.E. Westwood, S. Mallett, J.J. Deeks, J.B. Reitsma, and et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies Ann. Intern. Med. 155 8 2011 529 536
27. J.M. Bland The tyranny of power: is there a better way to calculate sample size? BMJ 339 2009 b3985
28. S. Rana, C.E. Powe, S. Salahuddin, S. Verlohren, F.H. Perschel, R.J. Levine, and et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia Circulation 125 7 2012 911 919
29. S. Rana, W.T. Schnettler, C. Powe, J. Wenger, S. Salahuddin, A.S. Cerdeira, and et al. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile Hypertens. Pregnancy 32 2 2013 189 201
30. S. Rana, S.A. Karumanchi, and M.D. Lindheimer Angiogenic factors in diagnosis, management, and research in preeclampsia Hypertension 63 2 2014 198 202
31. A.C. Staff, S.J. Benton, P. von Dadelszen, J.M. Roberts, R.N. Taylor, R.W. Powers, and et al. Redefining preeclampsia using placenta-derived biomarkers Hypertension 61 5 2013 932 942
32. M.S. Pepe, H. Janes, G. Longton, W. Leisenring, and P. Newcomb Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker Am. J. Epidemiol. 159 9 2004 882 890